Investment Rating - The report maintains a focus on innovative pharmaceuticals and medical devices, highlighting key A-share and H-share targets for investment [6][32]. Core Insights - The pharmaceutical sector showed a good recovery in Q3 2025, with overall revenue increasing by 0.6% year-on-year and net profit attributable to shareholders rising by 0.3% year-on-year [11][32]. - Medical equipment benefited from procurement recovery, with Q3 revenue and net profit growth of 10.6% and 0.6% year-on-year, respectively [11][32]. - Medical R&D outsourcing continued to achieve high growth, with Q3 revenue and net profit growth of 10.9% and 47.9% year-on-year [11][32]. - The offline pharmacy sector improved, with Q3 revenue and net profit growth of 2.1% and 37.8% year-on-year [11][32]. Summary by Sections 1. Focus on Innovative Pharmaceuticals and Medical Devices - Key A-share targets include Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Changchun High-tech Industry, Jiangsu Nhwa Pharmaceutical, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, APT Medical, and related target Guangdong Zhongsheng Pharmaceutical [6][32]. - Key H-share targets include Hansoh Pharmaceutical Group, 3SBio, Akeso, and related target Innovent Biologics, WuXi AppTec [6][32]. 2. Q3 2025 Pharmaceutical Sector Recovery - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year, with net profit attributable to shareholders up by 0.3% year-on-year [11][32]. - Specific segments such as medical devices and medical R&D outsourcing showed significant growth [11][32]. 3. October 2025 Market Performance - In October 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 1.8% while the SHCOMP rose by 1.9% [14][32]. - The relative premium of the pharmaceutical sector compared to all A-shares was at a normal level, with a current relative premium rate of 76.7% [23][32]. 4. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed, with the Hang Seng Healthcare index falling by 11.1% [24][32]. - In contrast, the U.S. S&P 500 healthcare sector rose by 3.5% [24][32].

Group 1 - The core viewpoint is that the Hong Kong Stock Connect Innovative Drug ETF has shown significant liquidity and growth in scale, with a recent net inflow of 56.08 million yuan and a total scale reaching 1.027 billion yuan [3] - The ETF's average daily trading volume over the past week was 133 million yuan, indicating strong investor interest [3] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Innovative Drug Index account for 71.11% of the index, highlighting concentration in key players like WuXi Biologics and Innovent Biologics [3] Group 2 - Analysts suggest that the recent adjustment in the innovative drug sector from August to October is relatively benign, with no negative changes in the industry fundamentals [4] - The pharmaceutical sector is viewed as being at a relative bottom, providing strong safety margins and potential for upward movement [4] - The 2026 strategy for the pharmaceutical and biotechnology industry emphasizes that innovative drugs will remain a key investment theme due to their growing international status and significant market potential [4]

Core Insights - The 8th China International Import Expo (CIIE) opened in Shanghai on November 5, 2023, with the theme "Open Up to Create New Opportunities, Collaborate to Share a New Future," attracting participation from 155 countries and regions, with over 4,108 foreign enterprises exhibiting, marking a new high in scale [1][3] Industry Developments - Multinational pharmaceutical companies are increasingly establishing R&D centers in China, with Astellas announcing its first innovation R&D center in Beijing on October 27, 2023, complementing its existing centers in Tokyo, San Francisco, Boston, Chicago, and Cambridge [3][4] - Major pharmaceutical companies like AstraZeneca and Boehringer Ingelheim have announced new investment plans in China, with AstraZeneca planning to invest $2.5 billion (approximately 18 billion RMB) and Boehringer Ingelheim over 5 billion RMB [4][5] - The trend of multinational companies acquiring innovative drug assets in China is accelerating, with companies like Takeda and Pfizer making significant investments to secure innovative drug assets, setting new records for business development (BD) transaction volumes in the Chinese innovative drug market [4][5] Market Positioning - China is evolving from a passive consumer market to a global innovation hub for multinational pharmaceutical companies, participating deeply in the entire process from R&D to production and sales [5][6] - By 2024, over 20% of the top 100 life sciences research institutions in the Nature Index will be in China, and the number of clinical trials initiated in China is expected to approach 2,000, reflecting a significant increase in China's innovation capabilities [6][7] Collaborative Trends - The number of multinational pharmaceutical companies establishing R&D centers in China has surged, with at least eight companies announcing new centers in October 2023 alone, including Eli Lilly, Pfizer, Bayer, and AstraZeneca [8][9] - Eli Lilly has invested over 20 billion RMB in China, focusing on a full industry chain layout from R&D to commercialization, and plans to continue expanding its local collaborations [10][11] Investment and Business Development - The total amount of innovative drug licensing agreements from China has surpassed $100 billion, with significant growth in transaction volumes and values, indicating a robust BD trend in the Chinese pharmaceutical market [15][16] - Notable transactions include Pfizer's $12.5 billion upfront payment for a breakthrough drug and Takeda's recent collaboration with Innovent Biologics involving a potential total deal value of up to $11.4 billion [16][17] Future Outlook - The trend of multinational companies seeking innovative resources in China is expected to continue, driven by the need to fill revenue gaps due to patent expirations in the U.S. and Europe [18][19] - The influence of Chinese biotech on the global market is growing, with projections indicating that by 2040, 35% of FDA-approved innovative drugs may originate from China [19]

Core Viewpoint - The Hong Kong stock market experienced fluctuations, but the biotechnology sector showed resilience, with leading stocks like BeiGene, Innovent Biologics, and 3SBio rebounding, while the Hong Kong Stock Connect Innovative Drug ETF (520880) demonstrated strong performance despite a slight decline at the end of the trading day [1][3]. Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a net subscription of approximately 86 million yuan yesterday, accumulating over 300 million yuan in the past ten days, indicating strong investor interest in the innovative drug sector [3]. - The ETF opened lower but quickly rebounded, closing down 0.54% while managing to record a positive daily line, suggesting a slight advantage for bullish forces [1][3]. Technical Analysis - The ETF formed a "中" character candlestick, reflecting intense competition between bulls and bears, with a closing bullish line indicating that bullish momentum may be strengthening [1]. - The MACD indicator shows an expanding red bar, further confirming the potential increase in bullish momentum [1]. Fundamental Analysis - The innovative drug sector is experiencing a global rise and commercialization phase, driven by accelerated business development (BD) overseas, a dense pipeline of products, and supportive policies [3]. - According to Dongwu Securities, innovative drugs will remain a key investment theme through 2026, with significant growth expected in international standing, BD expansion, and a shift towards profitability [3]. ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) exclusively tracks innovative drug research companies, excluding CXO firms, ensuring a pure focus on innovation [4]. - The top ten holdings in the ETF account for over 71% of the index, highlighting the dominance of leading innovative drug companies [4][5]. - The ETF has a total market size exceeding 2 billion yuan as of November 3, with an average daily trading volume of 474 million yuan, making it the largest and most liquid ETF tracking this index [5].

2025 年 11 月 5 日 星期三 每日大市点评 港股昨日恒生指数与国企股指数分别下跌 0.8%与 0.9%，大市成交回升 5.0%，但仍显著低于过去 1 月平均值。大型银行 股表现稳健，招行（3968 HK）、建行（939 HK）、工商银行（1398 HK）、中国银行（3988 HK）分别录 0.2%-2.4%涨幅， 但内地撤销黄金零售增值税抵扣，拖累现货金价一度失守每盎斯 4,000 美元，紫金矿业（2899 HK）下跌 5.4%，周大福 （1929 HK）、老铺黄金（6181 HK）、周生生（116 HK）继续下跌。由于阿里巴巴（9988 HK）、京东集团（9618 HK）、 美团（3690 HK）表现偏软，因此恒生科技股指数昨日下跌 1.8%。 昨晚美国股市三大指数分别下跌 0.5%-2.0%。消息指特斯拉（TSLA US）十大股东之一的挪威主权财富基金反对首席执行 官马斯克提出的 1 万亿美元的薪酬方案，导致特斯拉股价下跌。此外，由于美国政府的停摆时间已达 35 天并且拉平历史 最长记录，市场有担忧。 宏观动态： 韩国 2025 年 10 月 CPI 同比增加 2.4%，涨幅高于前值及彭博预测， ...

Core Insights - In October, the net value return of the GF CSI Hong Kong Innovative Drug ETF (QDII) decreased by 11.61% due to fluctuations in the Hong Kong stock market [1] - The fund's scale reached 24.889 billion yuan, with the top ten holdings including companies like Innovent Biologics, BeiGene, WuXi Biologics, and others [1] - The fund manager, Liu Jie, has over 10 years of experience in managing public funds since 2014 [1] Fund Performance - The GF CSI Hong Kong Innovative Drug ETF (QDII) reported a net value growth rate of -11.61% with a net value of 1.3337 yuan and a total scale of 24.889 billion yuan [2] - The GF CSI Hong Kong Innovative Drug ETF Initiated Link (QDII) C and A also experienced declines of over 11% in October, with net values of 1.3853 yuan and 1.3937 yuan respectively [2] - The largest holding, Innovent Biologics, saw a decline of 9.75% in October, while another major holding, CanSino Biologics, dropped over 19% [1]

Core Insights - The pharmaceutical industry is experiencing a structural change driven by the growth cycles of major products, with significant opportunities emerging in innovative drugs, medical devices, and consumer healthcare [3][6][31] - The demand for pharmaceuticals is expected to improve in 2026, supported by policies encouraging innovation and a recovery in domestic consumption [3][7] - The supply side of the pharmaceutical industry is characterized by high entry barriers due to patent protections and government regulations, which helps maintain a stable competitive environment [4][5] Group 1: Industry Trends - The aging population, urbanization, and changing disease patterns are making the pharmaceutical industry a perpetual growth sector [3] - The global pharmaceutical market has seen rapid expansion from 2009 to 2019, followed by a surge in demand due to COVID-19, and is now entering a phase of recovery and growth [3][6] - The Chinese pharmaceutical industry is expected to gradually produce world-class companies, with increasing recognition of Chinese innovative drug assets by multinational corporations (MNCs) [4][5] Group 2: Investment Opportunities - Opportunities in innovative drugs are highlighted, particularly in oncology, metabolic diseases, and autoimmune diseases, with a focus on next-generation therapies and precision medicine [6][31] - The demand for innovative drugs is expected to remain strong, with policies improving medical insurance payments and the upcoming launch of commercial insurance drug catalogs [7][31] - The medical device sector is anticipated to recover, with a focus on domestic demand and international expansion, particularly in areas with low domestic production rates [7][8] Group 3: Company Performance - Major pharmaceutical companies like Eli Lilly, AbbVie, and AstraZeneca are experiencing significant growth driven by key products, with Eli Lilly's Tirzepatide generating $24.8 billion in sales [12][15] - The report identifies specific companies such as Hengrui Medicine, Hansoh Pharmaceutical, and BeiGene as outperformers in the market, with strong pipelines and global competitiveness [7][8] - The report emphasizes the importance of mergers and acquisitions (M&A) and business development (BD) strategies for MNCs, with China becoming a significant source of projects for top global pharmaceutical companies [22][24]

Group 1: Liquidity and Fund Performance - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest saw an intra-day turnover of 7.76%, with a transaction volume of 76.0143 million yuan [2] - Over the past year, the average daily transaction volume of the ETF reached 116 million yuan [2] - In the past week, the ETF's scale increased by 39.7287 million yuan, ranking first among comparable funds [2] - The latest share count for the ETF reached 1.046 billion shares [2] - The ETF experienced a net inflow of 14.1619 million yuan, with a total of 46.8442 million yuan net inflow over three of the last five trading days [2] Group 2: Valuation and Index Composition - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the ETF is 31.84, which is in the 19.17th percentile over the past three years, indicating a valuation lower than 80.83% of the time in the last three years [2] - As of October 31, 2025, the top ten weighted stocks in the index include WuXi Biologics, Innovent Biologics, BeiGene, and others, collectively accounting for 71.11% of the index [2] Group 3: Policy and Market Outlook - The first version of the commercial insurance innovative drug directory is set to be released, with negotiations for the 2025 National Basic Medical Insurance Drug Directory concluding successfully [3] - A total of 120 domestic and foreign enterprises participated in the negotiations, with 127 drugs outside the directory involved in the bidding process [3] - The innovative drug industry is expected to remain in a golden development period, benefiting from advancements in clinical development and a rich pipeline of innovative drugs [3] - AI drug development and gene therapy technologies are anticipated to bring new breakthroughs in the coming years [3]

Fixed Income Research - In October, the issuance scale of credit bonds decreased slightly, with corporate bonds and medium-term notes increasing, while company bonds, short-term financing bonds, and targeted tools saw a decrease in issuance [3] - The overall credit bond yield declined, but the monthly average showed a mixed trend compared to September, with most credit spreads narrowing [3] - The market is expected to continue a downward trend in yields, with a cautious approach recommended for high-priced bonds, while focusing on the value of individual bonds [3][4] Fund Research - The total scale of public funds exceeded 36 trillion yuan, with a recent draft for performance comparison benchmarks released by the CSRC [5] - In the week from October 27 to October 31, the average return of equity funds was 0.20%, with a positive return ratio of 57.93% [6] - The ETF market saw a net inflow of 238.35 billion yuan, with significant inflows into stock ETFs [6][7] Financial Engineering Research - The A-share market saw most major indices decline in October, with the margin balance continuing to rise, reaching 24,784.70 billion yuan by the end of the month [8][9] - The financing balance increased by 900.17 billion yuan, while the average daily trading volume in the ETF market was 5,559.23 billion yuan [9][10] Industry Research - The pharmaceutical and biotechnology sector is seeing positive developments, with the recent ESMO conference showcasing advancements in Chinese innovative drugs [11] - The steel industry showed significant improvement in performance, with a net profit of 218.53 billion yuan in the first three quarters of 2025, compared to losses in the previous year [14][15] - The non-ferrous metals sector also performed well, with a revenue growth of 9.30% and a net profit increase of 41.55% in the first three quarters of 2025 [16][19]

Core Insights - The pharmaceutical industry is positioned as a perennial growth sector due to aging populations, urbanization, and changing disease profiles, with a strong recovery expected in 2025 after a downturn from 2022 to 2024, driven by both innovative drugs and medical devices [2][3] - Demand and supply dynamics will remain central to the pharmaceutical industry's research, with innovation cycles and policy adjustments influencing demand growth [2][3] - The supply side is characterized by limited supply and high entry barriers, with increasing participation of Chinese companies in international competition, leading to the emergence of world-class enterprises in the pharmaceutical sector [3][4] Industry Overview - The pharmaceutical industry is expected to see significant growth in 2025, driven by a resurgence in demand for innovative drugs and a recovery in domestic medical device needs, alongside strong external demand [2] - The demand for pharmaceuticals typically fluctuates with innovation and policy cycles, with a notable increase in overseas business development (BD) opportunities anticipated in 2025 [2][5] - The Chinese pharmaceutical sector is increasingly recognized globally, with local companies making strides in various niche markets [3][4] Investment Opportunities - Opportunities in innovative drugs are highlighted, particularly in oncology, metabolic diseases, and autoimmune diseases, with a focus on next-generation therapies and precision medicine [5][29] - The report emphasizes the importance of understanding the supply-demand structure and industry upgrades when conducting detailed research on specific segments within the pharmaceutical industry [4][5] - The report identifies key players and segments for investment, including CXO services, medical devices, and consumer healthcare, with specific companies recommended for increased holdings [6][5] Market Dynamics - The report outlines the competitive landscape among top global pharmaceutical companies, noting significant changes in rankings due to the performance of key products [11][19] - Chinese companies are becoming a major source of projects for multinational corporations (MNCs), with increasing transaction volumes and values in recent years [19][21] - The report discusses the strategic focus of MNCs on acquiring innovative assets and technologies to strengthen their market positions, particularly in oncology and metabolic disease sectors [12][18] Future Trends - The report anticipates breakthroughs in various therapeutic areas, including oncology, metabolic diseases, and autoimmune diseases, with a focus on innovative treatment modalities such as TCE and in vivo CAR-T [29][30] - The small nucleic acid field is expected to accelerate, with significant advancements anticipated in 2026 across multiple indications [29][30] - The report highlights the importance of collaboration and co-development models as a means for Chinese companies to enhance their global competitiveness [25][28]